Xpovio hits endpoints in Phase III multiple myeloma trial
The drug achieved a median progression-free survival of 13.93 months, compared to 9.46 months on Velcade (bortezomib).
Read More
Tag: Xpovio
Xpovio combo bags FDA approval for refractory multiple myeloma
The application was also granted Fast Track designation, and Xpovio received Orphan Drug designation.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
